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A fundamental question in the biology of sex differences has eluded
direct study in humans: How does sex-chromosome dosage (SCD)
shape genome function? To address this, we developed a systematic
map of SCD effects on gene function by analyzing genome-wide
expression data in humans with diverse sex-chromosome aneu-
ploidies (XO, XXX, XXY, XYY, and XXYY). For sex chromosomes, we
demonstrate a pattern of obligate dosage sensitivity among evolu-
tionarily preserved X-Y homologs and update prevailing theoretical
models for SCD compensation by detecting X-linked genes that
increase expression with decreasing X- and/or Y-chromosome dosage.
We further show that SCD-sensitive sex-chromosome genes regulate
specific coexpression networks of SCD-sensitive autosomal genes with
critical cellular functions and a demonstrable potential to mediate
previously documented SCD effects on disease. These gene coex-
pression results converge with analysis of transcription factor binding
site enrichment and measures of gene expression in murine knockout
models to spotlight the dosage-sensitive X-linked transcription factor
ZFX as a key mediator of SCD effects on wider genome expression.
Our findings characterize the effects of SCD broadly across the
genome, with potential implications for human phenotypic variation.
sex chromosomes | X-inactivation | sex differences | Turner syndrome |
Klinefelter syndrome
Disparity in sex-chromosome dosage (SCD) is fundamental tothe biological definition of sex in almost all eutherian
mammals: Females carry two X chromosomes, while males carry
an X and a Y chromosome. The presence of the Y-linked SRY
gene determines a testicular gonadal phenotype, while its absence
allows development of ovaries (1, 2). Sexual differentiation of the
gonads leads to hormonal sex differences that have traditionally
been considered the major proximal cause for extragonadal phe-
notypic sex differences. However, diverse studies, including recent
work in transgenic mice that uncouple Y chromosome and go-
nadal status, have revealed direct SCD effects on several sex-
biased metabolic, immune, and neurological phenotypes (3).
These findings together with reports of widespread tran-
scriptomic differences between preimplantation XY and XX
embryos (4) suggest that SCD has gene-regulatory effects inde-
pendently of gonadal status. However, the genome-wide conse-
quences of SCD remain poorly understood, especially in humans,
where experimental dissociation of SCD and gonadal status is not
possible. Understanding these regulatory effects is critical for
clarifying the biological underpinnings of phenotypic sex differ-
ences and the clinical features of sex-chromosome aneuploidy
(SCA) [e.g., Turner (XO) and Klinefelter (XXY) syndrome (5)],
which both involve altered risk for several common autoimmune
disorders (ADs) and neurodevelopmental disorders (e.g., systemic
lupus erythematosus and autism spectrum disorders) (6, 7). Here,
we explore the genome-wide consequences of SCD through
comparative transcriptomic analyses among humans across a
range of dosages including typical XX and XY karyotypes as well
as several rare SCA syndromes associated with 1, 3, 4, or 5 copies
of the sex chromosomes. We harness these diverse karyotypes
to dissect the architecture of dosage compensation among sex-
chromosome genes and to systematically map the regulatory ef-
fects of SCD on autosomal gene expression in humans. These
research goals also inform more general questions regarding the
effects of aneuploidy on genome function. In particular, the wide
range of chromosome-dosage variation in SCAs can help determine
if previously reported inverse effects of aneuploidy on gene ex-
pression in maize and Drosophila (i.e., negative cis and trans effects
of supernumerary chromosomes) (8, 9) also operate in humans.
We model SCD effects using gene-expression profiles in a total
of 471 lymphoblastoid cell lines (LCLs) from (i) a core sample of
68 participants (12 XO, 10 XX, 9 XXX, 10 XY, 8 XXY, 10 XYY,
and 9 XXYY) yielding for each sample genome-wide expression
data for 19,984 autosomal and 894 sex-chromosome genes using
the Illumina oligonucleotide BeadArray platform (Methods, SI
Appendix, Text S1, and Dataset S1), and (ii) an independent set of
validation/replication samples from 403 participants (6 XO, 146
XX, 22 XXX, 145 XY, 33 XXY, 16 XYY, 17 XXYY, 8 XXXY,
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and 10 XXXXY) with qRT-PCRmeasures of expression for genes
of interest identified in our core sample (Methods, SI Appendix,
Text S2, and Dataset S1). All SCA samples were from individuals
with nonmosaic aneuploidy.
Results
Extreme Dosage Sensitivity of Evolutionarily Preserved X-Y Gametologs.
First, to verify our study design as a tool for probing SCD effects on
gene expression and to identify core SCD-sensitive genes, we
screened all 20,878 genes in our microarray dataset to define which,
if any, genes showed a persistent pattern of significant differential
expression (DE) (Methods and SI Appendix, Text S1) across all
unique pairwise group contrasts involving a disparity in either X- or
Y-chromosome dosage (n = 15 and n = 16 contrasts, respectively)
(Fig. 1A). Disparities in X-chromosome dosage were always ac-
companied by statistically significant DE in four genes, which
were all X-linked: XIST (the orchestrator of X inactivation) and
three other genes known to escape X-chromosome inactivation
(HDHD1, KDM6A, and EIF1AX) (10). Similarly, disparities in Y-
chromosome dosage always led to statistically significant DE in six
Y-linked genes: CYorf15B, DDX3Y, TMSB4Y, USP9Y, UTY, and
ZFY. Observed expression profiles for these 10 genes perfectly
segregated all microarray samples by karyotype group (Fig. 1B) and
could be robustly replicated and extended using available qRT-
PCR data for of these genes in the independent sample of 403
LCLs from participants with varying SCD (Methods and SI Ap-
pendix, Text S1 and Fig. S1).
Strikingly, 8 of the 10 genes showing obligatory SCD sensitivity
(excepting XIST and HDHD1) are members of a class of 16 sex-
linked genes with homologs on both the X and Y chromosomes
(i.e., 16 X-Y gene pairs, henceforth referred to as “gametologs”)
(11) that are distinguished from other sex-linked genes by (i)
their selective preservation in multiple species across ∼300 My of
sex-chromosome evolution to prevent male–female dosage dis-
parity, (ii) the breadth of their tissue expression from both sex
chromosomes, and (iii) their key regulatory roles in transcription
and translation (Dataset S2) (11, 12). Broadening our analysis to
all 14 X-Y gametolog pairs present in our microarray dataset, we
found that these genes as a group exhibit a heightened degree of
SCD sensitivity that distinguishes them from other sex-linked
genes (Fig. 1C, empirical P < 0.0001). These findings provide
direct evidence that the evolutionary maintenance, broad tissue
expressivity, and enriched regulatory functions of X-Y gametologs
(12) are indeed accompanied by a distinctive pattern of dosage
sensitivity, which firmly establishes these genes as candidate reg-
ulators of SCD effects on wider genome function.
Observed Sex-Chromosome Dosage Effects on X- and Y-Chromosome
Genes Modify Current Models of Dosage Compensation. We next
harnessed our study design to test the canonical (four-class) model
for SCD compensation, which defines four mutually exclusive clas-
ses of sex-chromosome genes that would be predicted to have dif-
fering responses to changing SCD (13): (i) pseudoautosomal region
(PAR) genes, (ii) Y-linked genes, (iii) X-linked genes that undergo
X-chromosome inactivation (XCI), and (iv) X-linked genes that
escape XCI (XCIE). Under the four-class model, PAR genes would
be predicted to increase their expression with increases in X- or Y
chromosome count, whereas expression of Y-linked genes would
increase linearly with mounting Y-chromosome count. Due to the
nonbinary nature of gene silencing with XCI (14), theorized SCD
effects on the expression of XCI and XCIE genes represent the
extreme ends of an X-chromosome dosage-sensitivity continuum: an
X-linked gene that undergoes full silencing with XCI would show no
expression change with changes in X-chromosome dosage, whereas
an X-linked gene that undergoes complete escape from
X-chromosome inactivation would show a linear increase in ex-
pression with increasing X-chromosome count.
To test this canonical four-class model, we performed un-
supervised k-means clustering of all sex-chromosome genes by
their average expression in each of the seven karyotype groups
represented in our microarray dataset (after normalization by
average expression across all karyotype groups). We then com-
pared this empirically defined grouping with that given a priori by
the four-class model (Methods and SI Appendix, Text S3). k-Means
clustering distinguished six gene clusters (Fig. 2A and SI Appendix,
Fig. S2A) which were reproducible across 1,000 bootstrap draws
from the LCL microarray dataset sample pool (SI Appendix, Text
S3 and S4 and Fig. S2B). These clusters consisted of a single large
set of 773 genes with low or undetectable expression levels in most
samples (median detection rate of 4/68 samples) and no signifi-
cant SCD sensitivity, and five smaller groups of genes (k1–k5) with
high SCD sensitivity (Fig. 2A, SI Appendix, Fig. S2 A–C, and
Datasets S3 and S4). The set of 773 genes with low expression by
microarray also showed low/undetectable expression by RNA-
sequencing (RNA-seq) in an independent study of 343 LCL
lines from the Genotype-Tissue Expression (GTEx) project (SI
Appendix, Text S4) (15) and is not considered further in this report.
Each of the five SCD-sensitive clusters of sex-chromosome
genes detected by k-means (k1–k5) was specifically enriched for
a distinct set of genes within the a priori four-class model (Fig.
2B), defining a PAR cluster (k1), Y cluster (k2, preferential
overrepresentation of Y gametologs: odds ratio = 5,213, P =
1.3 × 10−15), XCIE cluster (k3, preferential overrepresentation
of X gametologs: odds ratio = 335, P = 3.4 × 10−11), XCI cluster
(k4), and a separate cluster for XIST (k5) (Fig. 2B). For three of
these clusters—Y-linked, XCIE, and XCI—we observed profiles
of dosage sensitivity across karyotype groups that deviated from
those predicted by the four-class model (Fig. 2 C and D).
Mean expression of the Y cluster increased in a sublinear
stepwise fashion with greater Y-chromosome dosage, indicating
that its constituent Y-linked genes may be subject to active dosage
compensation. Groupwise fold changes observed by microarray
for three out of three of these genes were highly correlated with
groupwise fold changes observed by qRT-PCR in an independent
sample of 403 participants with varying SCD (SI Appendix, Text S2
and Fig. S2E). Mean expression of the XCIE cluster increased
with X-chromosome dosage (as predicted by the four-class model)
but did so in a sublinear fashion (Fig. 2 C and D). For seven
XCIE-cluster genes with recently published allelic expression
imbalance data from LCLs in a female with skewed X-inactivation
(16), we found that observed sublinear effects of X-chromosome
dosage on expression by microarray were largely consistent with
gene-level estimates of incomplete XCIE by RNA-seq (SI Ap-
pendix, Text S5 and Fig. S2D). Mean expression of the XCI cluster
deviated from predictions of the four-class model by showing a
Fig. 1. Consistent gene-expression changes with altered sex-chromosome
dosage. (A) Cross-table showing all pairwise SCD group contrasts within the
microarray dataset shaded by X- and/or Y-chromosome disparity. (B) Ex-
pression heatmap for the 10 genes that show DE across all contrasts in-
volving disparity in X- or Y-chromosome count. The column color bar
encodes SCD group membership for each sample. (C) Density plots showing
the observed mean proportion of expression variance explained by SCD for
14 gametolog genes (red line) vs. null distribution (black line) of this variable
for 10,000 randomly sampled sets of nongametolog sex-linked genes of
equal size. Results are provided separately for X and Y chromosomes.






statistically significant inverse relationship with X-chromosome
dosage (coefficient for linear effect of X-chromosome count on
expression = −0.12, P = 3.8 × 10−15). This phenomenon was re-
producible for 60/66 (91%) of individual genes within the cluster
(P < 0.05 for negative linear effect of X-chromosome count on
expression). Furthermore, noting the relatively small log2 fold
change (log2FC) values for reduced XCI-cluster expression with
increasing X-chromosome count (Fig. 2D and Dataset S3), we
also verified that for most (89%) XCI-cluster genes, observed
log2FC differences in expression between XXX and XO groups
were statistically significant relative to null fold-change distribu-
tions estimated within the same microarray dataset (SI Appendix,
Text S6). Thus, observed patterns of gene expression for X-linked
genes within the XCI-enriched cluster suggest that increasing X
copy number may not involve only the silencing of these genes
from the additional inactive X chromosome but also a further
repression of their expression from the single active X chromo-
some. Remarkably, expression of the XCI cluster was also signif-
icantly decreased by the presence of a Y chromosome, at the level
of both mean cluster expression (coefficient for linear effect of Y-
chromosome count on expression = −0.09, P = 1.4 × 10−14) and
expression profiles of 48/66 individual cluster genes (P < 0.05 for
negative linear effect of Y count on expression). The XCIE cluster
manifested an inverted version of this effect whereby increases in
Y-chromosome dosage were associated with increased gene ex-
pression (P < 6.2 × 10−11 for mean cluster expression and P < 0.05
for 23/39 cluster genes). These findings provide evidence that Y-
chromosome status in humans may influence the expression level
of X-linked genes independently of circulating gonadal factors.
We took several steps to further probe the unexpected modes
of dosage sensitivity observed for the XCI cluster and XCIE
cluster. First, we established that observed patterns of dosage
sensitivity for these clusters held when analysis was restricted to
X-linked genes with only high-confidence annotations for XCIE
and XCI status, respectively (Fig. 2D), suggesting that the ob-
served expression profiles were unlikely to be explained by
misclassification of X-linked genes by XCI status. Second, we
confirmed that the distinct expression profiles for these two gene
clusters were reproducible at the level of individual genes and
samples. Indeed, unsupervised clustering of microarray samples
based on expression of XCI- and XCIE-cluster genes distin-
guished three broad karyotype groups: females with one X
chromosome (XO), males with one X chromosome (XY and
XYY), and individuals with an extra X chromosome (XXX,
XXY, and XXYY) (Fig. 2E). Third, we validated our data-driven
discovery of XCI and XCIE clusters against independently
generated X-chromosome annotations (Fig. 2F) which detail
three distinct genomic predictors of inactivation status for X-
linked genes. Specifically, XCI-cluster genes were relatively
enriched (and XCIE cluster genes relatively impoverished) for
(i) having lost a Y-chromosome homolog during evolution (χ2 =
10.9, P = 0.01) (17), (ii) being located in older evolutionary strata
of the X chromosome (χ2 = 22.6, P = 0.007) (18), and (iii)
bearing heterochromatic markers (χ2 = 18.4, P = 0.0004) (19).
Finally, qRT-PCR assays in LCLs from an independent sam-
ple of 403 participants with varying SCD validated the fold
changes observed in microarray data for five of six of the most
SCD-sensitive XCIE- and XCI-cluster genes (Methods and SI
Appendix, Text S2 and Fig. S2F). To independently extend these
observations, we measured gene expression by qRT-PCR in
karyotype groups not represented in our microarray dataset (XXXY
Fig. 2. Data-driven partitioning of sex-chromosome genes by dosage sen-
sitivity. (A) 2D multidimensional scaling (MDS) plot of sex-chromosome
genes by their mean expression profiles across all seven SCD groups. Genes
are coded by both the four-class model (shape) and k-means cluster
grouping (color). MDS2 arranges X-linked genes along the established gra-
dient of X-linked dosage sensitivity that ranges from extreme XCIE (XIST) to
full XCI. A cluster of low/nonexpressed genes that lack SCD sensitivity is
colored gray (SI Appendix, Text S4 and Fig. S2). (B) Cross-table showing en-
richment of k-means clusters for four-class model gene groups. (C) Dot and
line plots showing observed (solid colored) and predicted (dashed gray) mean
expression for each k-means gene cluster across karyotype groups. (D) Close-
up of observed (solid colored) vs. predicted (dashed gray) mean expression
profiles of XCIE and XCI gene clusters. Observed expression profiles still
counter predictions when analysis is restricted to core genes in each cluster
with XCIE/XCI statuses that have been confirmed across three independent
reports (thick colored line). (E) Heatmap showing normalized (vs. XX mean)
expression of dosage-sensitive genes in the XCIE and XCI clusters (rows) for
each sample (columns; the color bar encodes the SCD group). (F) Pie-charts
showing that XCIE and XCI gene clusters from k-means display mirrored
over/underrepresentation for three genomic features that have been linked
to XCIE in prior research: (i) persistence of a surviving Y-linked homolog; (ii)
location within younger evolutionary strata of the X chromosome; and (iii)
presence of euchromatic vs. heterochromatic epigenetic markers.
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and XXXXY) (Methods and SI Appendix, Text S1) and were able to
confirm reduction in expression with greater X-chromosome dosage
for two of three XCI-cluster genes, NGFRAP1 and CXorf57 (SI
Appendix, Fig. S2G,) and Y-chromosome dosage effects upon ex-
pression for four of six X-linked genes from the XCI and XCIE
clusters (down-regulation: NGFRAP1 and CXorf57; up-regulation:
PIM2, and PRKX) (SI Appendix, Fig. S2H). Taken together, these
findings update the canonical four-class model of SCD compensation
for specific Y-linked and X-linked genes and expand the list of
X-linked genes capable of mediating wider phenotypic consequences
of SCD variation. The existence of X-linked genes that decrease
expression with increasing X-chromosome count also indicates that
previously documented inverse effects of aneuploidy on gene ex-
pression in maize and Drosophila (8, 9) are also seen in humans.
Context-Specific Disruption of Autosomal Expression by Sex-
Chromosome Aneuploidy. We next leveraged the diverse SCAs
represented in our study to assess how SCD variation shapes ex-
pression on a genome-wide scale. By counting the total number of
differentially expressed genes (DEGs) (Methods) in each SCA
group relative to its respective euploid control (i.e., XO and XXX
compared with XX; XXY, XYY, and XXYY compared with XY),
we detected order-of-magnitude differences in DEG count among
SCAs across a range of log2FC cutoffs (SI Appendix, Fig. S3 A and
B). We observed an order-of-magnitude increase in DEG count
with X-chromosome supernumeracy in males vs. females, which,
although previously undescribed, is congruent with the more se-
vere phenotypic consequences of X-supernumeracy in males vs.
females (20). Overall, increasing the dosage of the sex chromo-
some associated with the sex of an individual (i.e., X in females
and Y in males) had a far smaller effect than other types of SCD
change. Moreover, the ∼20 DEGs seen in XXX contrasted
with >1,200 DEGs in XO, revealing a profoundly asymmetric
impact of X-chromosome loss vs. gain on the transcriptome of
female LCLs, which echoes the asymmetric phenotypic severity of
X-chromosome loss (Turner syndrome) vs. gain (XXX) syn-
dromes in females (6). The large number of DEGS in XO in-
cluded a similar proportion with increases vs. decreases in
expression (e.g., 782 XO > XX, 605 XO < XX). Autosomal genes
accounted for >75% of all DEGs in females with X-monosomy
(XO) and males with X-supernumeracy (XXY and XXYY)
but <30% DEGs in all other SCD groups (Methods and SI Ap-
pendix, Fig. S3C). These results reveal that SCD changes vary
widely in their capacity to disrupt genome function and indicate
that differential involvement of autosomal genes is central to this
variation. Moreover, SCA differences in LCL DEG count broadly
recapitulate SCA differences in phenotypic severity.
Sex-Chromosome Dosage Regulates Large-Scale Gene Coexpression
Networks. To provide a more comprehensive systems-level per-
spective on the impact of SCD on genome-wide expression
patterns, we leveraged weighted gene coexpression network
analysis (WGCNA) (Methods and SI Appendix, Text S7) (21).
This analytic approach uses the correlational architecture of
gene expression across a set of samples to detect sets (modules)
of coexpressed genes. Using WGCNA, we identified 18 in-
dependent gene-coexpression modules in our dataset (Dataset
S5). We established that these modules were not artifacts of the
codifferential expression of genes between groups by demon-
strating their robustness to removal of all group effects on gene
expression by regression (SI Appendix, Fig. S4A) and after specific
exclusion of XO samples (SI Appendix, Fig. S4B), given the extreme
pattern of DE in this karyotype. We focused further analysis on
modules meeting two independent statistical criteria after correction
for multiple comparisons: (i) a significant omnibus effect of SCD
group on expression and (ii) significant enrichment for one or more
gene ontology (GO) process/function terms (Methods, Fig. 3 A and
B, SI Appendix, Text S7, and Dataset S5). These steps defined eight
functionally coherent and SCD-sensitive modules (Blue, Brown,
Green, Purple, Red, Salmon, Tan, and Turquoise). Notably, the SCD
effects we observed on genome-wide expression patterns appeared to
be specific to shifts in sex-chromosome gene dosage, as application of
our analytic workflow to publically available genome-wide Illumina
BeadArray expression data from LCLs in patients with trisomy 21
(Down syndrome) revealed a profile of genome-wide expression
change dissimilar to that observed in sex-chromosome trisomies (SI
Appendix, Text S8 and Fig. S4C and Dataset S6).
To specify SCA effects on module expression, we compared all
aneuploidy groups with their respective gonadal controls (Fig. 3C).
Statistically significant differences in modular eigengene expression
were seen in the XO, XXY, and XXYY groups, as is consistent with
these karyotypes causing larger total DEG counts than the other
SCD variations (SI Appendix, Fig. S3A). The largest shifts in module
expression were seen in XO and included robust up-regulation of
the protein trafficking (Turquoise), metabolism of noncoding RNA
(Brown), and phosphatidylinositol metabolism (Tan) modules,
alongside down-regulation of the cell-cycle progression, DNA
replication/chromatin organization (Blue and Salmon), glycolysis
(Purple), and responses to endoplasmic reticular stress (Green)
modules. Module DE in groups with supernumerary X chromo-
somes on an XY background (i.e., XXY and XXYY) involved an
inversion of some XO effects, i.e., down-regulation of protein
trafficking (Turquoise) and up-regulation of cell-cycle progression
(Blue) modules, plus a more karyotype-specific up-regulation of the
immune response pathways (Red) module.
The distinctive up-regulation of immune-system genes in
samples of lymphoid tissue from males carrying a supernumerary X
chromosome carries potential clinical relevance for one of the best-
established clinical phenotypes in XXY and XXYY syndromes: a
strongly (up to 18-fold) elevated risk for ADs such as systemic lupus
Fig. 3. WGCNA of sex-chromosome dosage effects. (A) Dot and line plots
detailing mean expression (± 95% CI) by SCD group for eight SCD-sensitive and
functionally coherent gene-coexpression modules. (B) Top two GO term enrich-
ments for each module exceeding the threshold for statistical significance (dashed
red line). (C) Heatmap showing statistically significant DE of gene-coexpression
modules between karyotype groups. (D) Cross-tabulation showing enrichment of
Turquoise, Brown, Blue, and Green modules for the dosage-sensitive clusters of
sex-chromosome genes detected by k-means. (E) Gene-coexpression network for
the Blue module showing the top decile of coexpression relationships (edges)
between the top decile of SCD-sensitive genes (nodes). Nodes are positioned
in a circle for ease of visualization. Node shape distinguishes autosomal
(circle) from sex-chromosome (square) genes. Sex-chromosome genes within
the Blue module are colored according to their k-means cluster designation.
Larger node and gene name sizes reflect greater SCD sensitivity. Edge width
indexes the strength of coexpression between gene pairs.






erythematosus, Sjögren syndrome, and diabetes mellitus (7). In
further support of this interpretation, we found the Red module to
be significantly enriched (P = 0.01 by Fisher’s test and P = 0.01 by
gene set permutation) for a set of known AD-risk genes compiled
from multiple large-scale genome-wide association studies (GWAS)
(Methods and SI Appendix, Text S7). The two GWAS-implicated
AD-risk genes showing strongest connectivity within the Red
module and up-regulation in males bearing an extra X chro-
mosome were CLECL1 and ELF1, indicating that these two
genes should be prioritized for further study in mechanisms of
risk for heightened autoimmunity in XXY and XXYY males.
Collectively, these results represent a systems-level charac-
terization of SCD effects on genome function and provide
convergent evidence that increased risk for AD risk in XXY
and XXYY syndromes may be due to an up-regulation of
immune pathways by supernumerary X chromosomes in male
lymphoid cells.
To test for evidence of coordination between the expression
changes in sex-chromosome genes imparted by SCD (Fig. 2) and
the genome-wide transcriptomic variations detected through
WGCNA (Fig. 3A), we asked if any SCD-sensitive gene-coexpression
modules were enriched for one or more of the five SCD-sensitive
clusters of sex-chromosome genes defined by k-means analysis (Fig.
2). FourWGCNAmodules, all composed of >95% autosomal genes,
showed such enrichment (Fig. 3D). XCI-cluster genes were enriched
within Turquoise and Brown coexpression modules, indicating that
the inverse cis effects of X-chromosome dosage on the expression of
XCI-cluster genes (Fig. 2) are closely coordinated with inverse trans
effects of X-chromosome dosage on autosomal expression (Fig. 3 A
and C). Conversely, XCIE-cluster genes were enriched within the
Green and Blue coexpression modules, with the Blue module being
further distinguished by an additional enrichment in PAR-cluster
genes and inclusion of XIST (Fig. 3D). We generated a network vi-
sualization to examine more closely SCD-sensitive genes and gene-
coexpression relationships within the Blue module (Methods and
Fig. 3E). This network highlights the high SCD sensitivity of XIST,
select PAR genes (SLC25A6 and SFRS17A), and multiple X-linked
genes from X-Y gametolog pairs [EIF1AX, KDM6A (UTX), ZFX,
and PRKX] and shows that these genes are closely coexpressed with
multiple SCD-sensitive autosomal genes including ZWINT,
TERF2IP, and CDKN2AIP.
Our detection of highly organized coexpression relationships be-
tween SCD-sensitive sex-linked and autosomal genes hints at specific
regulatory effects of dosage-sensitive sex-chromosome genes in me-
diating the genome-wide effects of SCD variation. To test this and to
elucidate potential regulatory mechanisms, we performed an un-
biased transcription factor binding site (TFBS) enrichment analysis
of genes within the Blue, Green, Turquoise, and Brown WGCNA
modules (Methods and SI Appendix, Text S9). This analysis con-
verged on a single transcription factor—ZFX, encoded by the
X-linked member of an X-Y gametolog pair—as the only SCD-
sensitive transcription factor (see SI Appendix, Fig. S1 for qRT-
PCR validation) showing significant TFBS enrichment in one or
more modules. Remarkably, the gene ZFX was itself part of the Blue
module, and ZFX-binding sites were enriched not only among Blue
and Green module genes (increasing in expression with increasing
X-chromosome dose) but also among Brown module genes that are
down-regulated as X-chromosome dose increases (SI Appendix, Fig.
S4D). To directly test if changes in ZFX expression are sufficient to
modify the expression of Blue, Green, or Brown module genes in
immortalized lymphocytes, we harnessed existing gene-expression
data from murine T-lymphoblastic leukemia cells with and without
ZFX knockout (Gene Expression Omnibus GSE43020) (22). These
data revealed that genes down-regulated by ZFX knockout in mice
have human homologs that are specifically and significantly over-
represented in Blue (e.g., PARP16 and TCEA1; odds ratio = 2.4, P =
0.0005, Fisher’s test) and Green (e.g., BAG3 and CCDC117; odds
ratio = 2.4, P = 0.005, Fisher’s test) modules (P > 0.1 for each of the
other six WGCNA modules), providing experimental validation of
our hypothesized regulatory role for ZFX.
Discussion
In conclusion, our study, which systematically examined gene-
expression data from 471 individuals representing nine different sex-
chromosome karyotypes, yields several insights into sex-chromosome
biology with consequences for basic and clinical science. First, our
discovery and validation of X-linked genes that are up-regulated by
reducing X-chromosome count (so that their expression is elevated
in XO vs. XX, for example) runs counter to dominant models of sex-
chromosome dosage compensation in mammals. This noncanonical
mode of SCD sensitivity modifies current thinking regarding which
subsets of X-chromosome genes could contribute to sex- and SCA-
biased phenotypes (23). An inverse effect of X-chromosome dosage
on X-chromosome gene expression could reflect repression of X-
linked genes on the active X-chromosome by PAR or X-linked genes
that are expressed from inactive X chromosomes or by stoichio-
metric imbalances (see below) between the products of PAR/X-
linked and autosomal genes. Alternatively, inverse effects of
X-chromosome dosage may reflect changes in nuclear heterochro-
matin dosage that would follow from varying numbers of inactivated
X-chromosomes. The potential for heterochromatin-mediated con-
sequences of SCD variation has been documented in mice, Dro-
sophila, and humans (24, 25). Our findings also modify classic models
of sex-chromosome biology by identifying X-linked genes that vary in
their expression as a function of Y-chromosome dosage, indicat-
ing that the phenotypic effects of normative and aneuploid varia-
tions in Y-chromosome dose could theoretically be mediated by
altered expression of X-linked genes. Moreover, the discovery of
Y-chromosome dosage effects on X-linked gene expression provides
routes for competition between maternally and paternally inherited
genes beyond the previously described mechanisms of parental im-
printing and genomic conflict, with consequences for our mecha-
nistic understanding of sex-biased evolution and disease (26).
Beyond their theoretical implications, our data help pinpoint
specific genes that are likely to play key roles in mediating SCD
effects on wider genome function. Specifically, we establish that a
distinctive group of sex-linked genes notable for their evolutionary
preservation as X-Y gametolog pairs across multiple species and the
breadth of their tissue expression in humans (12) are further dis-
tinguished from other sex-linked genes by their exquisite sensitivity to
SCD and exceptionally close coexpression with SCD-sensitive au-
tosomal genes. These results add critical evidence in support of the
idea that X-Y gametologs play a key role in mediating SCD effects
on wider genome function. In convergent support of this idea, we
show that (i) multiple SCD-sensitive modules of coexpressed auto-
somal genes are enriched with TFBS for an X-linked transcription
factor from the highly dosage-sensitive ZFX-ZFY gametolog pair and
(ii) ZFX deletion causes targeted gene-expression changes in such
modules. Inclusion of ZFX in a coexpression module (Blue) with
enriched annotations for chromatin organization and cell-cycle
pathways is especially striking given the rich bodies of experimen-
tal data which have independently identified ZFX as a key regulator
of cellular renewal and maintenance (27).
Gene-coexpression analysis also reveals the diverse domains of
cellular function that are sensitive to SCD, spanning cell-cycle
regulation, protein trafficking, and energy metabolism. Many of
these processes are known to be sensitive to shifts in cellular kar-
yotype more generally (28), although we find several which appear
to be specific to shifts in SCD, as they are not induced by trisomy of
chromosome 21. Furthermore, gene-coexpression analysis of SCD
effects dissects out specific immune activation pathways that are up-
regulated by supernumerary X-chromosomes in males and enriched
for genes known to confer risk for ADs that are overrepresented
among males bearing an extra X chromosome. Thus, we report a
coordinated genomic response to SCD that could potentially ex-
plain observed patterns of disease risk in SCA. Finally, coordinated
genomic responses to SCA also feature extensive trans-acting in-
verse effects of SCD on autosomal expression. Such inverse trans
effects of aneuploidy have been well described in model systems
such as maize and Drosophila but remain relatively undocumented
in humans (8, 9). Inverse trans effects in these model systems have
been linked to specific regulatory genes on aneuploidy chromosomes
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and altered stoichiometry between the products of these genes and
partner molecules encoded by nonaneuploid chromosomes (29),
suggesting that similar processes may underlie our observations in
humans. Collectively, our findings help refine current models of sex-
chromosome biology and advance our understanding of genomic
pathways through which sex chromosomes can shape phenotypic
variation in health and sex-chromosome aneuploidy.
Materials and Methods
Acquisition and Preparation of Biosamples. RNA was extracted by standard
methods (Qiagen) from LCLs from 471 participants recruited through studies of
SCA at the NIH Health Intramural Research Program and Thomas Jefferson Uni-
versity (Dataset S1) (30). Sixty-eight participants provided RNA samples for
microarray analyses (12 XO, 10 XX, 9 XXX, 10 XY, 8 XXY, 10 XYY, and 9 XXYY),
and 403 participants provided RNA samples for a separate qRT-PCR validation/
extension study (6 XO, 146 XX, 22 XXX, 145 XY, 33 XXY, 16 XYY, 17 XXYY,
8 XXXY, and 10 XXXXY). The microarray and qRT-PCR samples were fully in-
dependent of each other (biological replicates), with the exception of four XO
participants in themicroarray studywho each also provided a separate LCL sample
for the qRT-PCR study. All participants with X/Y aneuploidy were nonmosaic based
on visualization of at least 50 metaphase spreads in peripheral blood. Stability of
karyotype across LCL derivation was confirmed by chromosome FISH in all
members of a randomly selected subset of nine LCL samples representing each of
the four supernumerary SCA groups included in our microarray analysis. The
research protocol was approved by the institutional review board at the
National Institute of Mental Health, and informed consent or assent was
obtained from all children who participated in the study, as well as consent
from their parents if the child was under the legal age of majority.
Microarray Data Preparation, Differential Expression Analysis, Annotation, and
Probe Selection. Gene expression was profiled using the Illumina HT-12 v4 Ex-
pression BeadChip Kit (Illumina, Inc.). Preprocessing and annotation ofmicroarray
data (SI Appendix, Text S1) resulted in high-quality measures of expression for
19,984 autosomal and 894 sex-chromosome genes in each of 68 independent
samples from seven different karyotype groups. For each SCD group contrast,
differentially expressed genes survived correction for multiple comparison across all
probes, with q (the expected proportion of falsely rejected nulls) set at 0.05, and
showed a log2FC >0.26. This log2 cutoff was selected empirically, by defining the
log2 fold increment associated with the greatest drop in DEG count for each SCA
group and averaging these thresholds all five groups (SI Appendix, Fig. S3).
Testing the Four-Class Model. All 894 sex-chromosome genes with microarray
expression datawere uniquely assigned to PAR, Y-linked, XCIE, and XCI classes
using known PAR boundaries and a consensus classification of X-linked genes
by X-inactivation/escape status (SI Appendix, Text S3) (10). These a priori gene
groupings were compared with groups defined by k-means clustering of
genes by their profile of mean expression across SCD groups. k-Means clus-
tering defined five clusters of expressed genes with SCD sensitivity and a re-
mainder cluster of genes with low or undetectable expression levels across all
samples (SI Appendix, Text S3 and Fig. S2A). k-Means cluster stability was
assessed using bootstrap methods (SI Appendix, Text S4 and S5), and cluster
overlaps with four-class model groupings were assessed by two-tailed Fisher’s
tests. General linear models were used to estimate X- and Y-chromosome
dosage effects on mean expression of each k-means gene cluster (SI Appen-
dix, Text S3). χ2 tests were used to compare k-means clustering of X-linked
genes with independently published X-chromosome annotations for (i)
chromatin state (19), (ii) evolutionary strata (18), and (iii) presence vs. absence
of a surviving Y-chromosome homolog (SI Appendix, Text S3) (10).
Comparison of DEG Count and Genomic Distribution Across SCA Groups. Total
DEG counts were compared across SCD groups across a range of log2FC
cutoffs as described above and are reported in SI Appendix, Fig. S3 A and B.
Observed DEG counts across four genomic regions—autosomal, PAR,
Y-linked, and X-linked—were compared with the background distribution of
total gene counts across these regions using the prop.test function in R.
qRT-PCR Validation of Differentially Expressed Genes in Microarray. For se-
lected genes showing significant DE between karyotype groups in our core
sample, we used qRT-PCR measures of gene expression (Fluidigm) to validate
and extent observed fold changes in an independent sample of 403 partic-
ipants representing all the karyotypes in our core sample plus two additional
SCAs: XXXY and XXXXY (SI Appendix, Text S2, Dataset S1).
WGCNA. Gene-coexpression modules were generated and assessed for re-
producibility using the R package WGCNA (SI Appendix, Text S7). Modular GO
term enrichments were assessed using GO elite (31) and Gorilla (32). Fisher’s exact
test and resampling methods were used to assess modular enrichments for AD-
risk genes from a reference catalog of GWAS findings (https://www.ebi.ac.uk/
gwas/). See SI Appendix, Text S8 for details of TFBS enrichment analysis and ex-
perimental validation for the hypothesized regulatory role of ZFX assessed using
gene-expression data from lymphocytes in a murine ZFX-knockout model (22).
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